08/17/2011 10:03 FAX 2024935142 FAA 

AUG. 16, 2011 5:0SPM REGULATORY AFFAIRS 

DMS 

JO. 24! 

@O01/02 3 

P. 1/23 

• 4 

Express 

FACSIMILE TRANSMISSION SHEET 

DATE: 

TO 

8/36/2011 TIME: 5;00p.m. CP T 

Federal Aviation Administration 

TELECOPIER NUMBER: 

FROM: 

202-493-5142 

CYNTHIA A. CHANDLER-SNELL 

Staff Attorney 

Legal and Regulatory Affairs 

FEDEX EXPRESS 

3620 Hacks Cross Road 

Building B-3''* Floor 

Memphis, TN 35125 

Phone:(901)434-836] 

Telecopier: (901) 434-8283 

301 0-0?'/I 

If you donot receive all 23 page(s), inclusive of this cover sheet, please contact 

my Administrative Assistant, Tiffany at (901) 434-8576, 

Message: 

THE INFORMAnON CONTAINED IN THIS FACSIMILE MESSAGE IS ATTORNEY PRIVILEGED 

AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL 

OR ENITTY NAMED ABOVE. EF THE READER OF THIS MESSAGE IS NOT THE INTENDED 

RECIPIENT, OR THE EMPLOYEE OR AGENT REPONSTBLE TO DELIVER IT TO THE INTENDED 

R£CIPIF^^:, YOU AR£ HERE NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR 

COPYING OF THE COMMUNICATION IS STRICTLY PROHIBFTED. IF VOU HAVE RECEIVED 

THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND 

RETRUN TKE ORIGINAL MESSAGE TO US AT THE ABOVE ADDDRESS. 
08/17/201 1 100 4 FAX 2024335U 2 FAA ^ OMS (2)002/023 

AUG. 16. 201 1 5; 09PM [ibGULATOSY AFFAIRS WO. 24 5 P. 2/2 5 

Ji^PARTMEMTCF 

-\MSP0RWI0N 

UNITED STATES OF AMERICA . C;'-:i:T OFERAllC'NS 

DEPARTMENT OF TRANSPORATION 

OFFICE OF HEARINGS 

WASHINGTON, DC 

m i AUG ! 1 P hOO 

In the Matter of FAA DOCKET NO CP1ONMOO11 

FEDERAL EXPRESS CORPORATION FAA CASE NO 200SNM700127 

In the Matter of FAA DOCKET NO CPl ONMOO 10 

CORPORATE AIR FAA CASE NO 2008NM700126 

FEDEX AND CORPORATE AIR^S RESPONSE TO FAA.^S MOTION IN LIMINE 

AND REQUEST FOR EXTEOrTED RULING 

THE HONORABLE RICHARD C. GOODWIN 

COME NOW the Respondents, Federal Express Corporation (hereinafter 

^TedEx'O and Corporate Air, and in response to the FAA's Motion in Limine and 

Request for Expedited Ruling submits the following: 

1. It is admitted that FedEx, Corporate Air, and the FAA exchanged discovcrv' 

on the agreed-upon dale of August 8, 2011, wherein FedEx and Corporate 

Air named Bob Richard as a poteatial w-itness. 

2. It is admitted that Mr. Richard is the former Deputy- Administrator for 

Hazardous Material Safety for the Pipeline and Hazardous Materials Safety 

Administration (PHN'ISA). FedEx and Corporate Air agree that there are 

requirements governing the matters and extent to which Mr. Richard may 

testify, which were addressed in the discovery response. FedEx and 

Corporate Air did not name Mr. Richard as an expert or opinion witoess and 

have no intentions of using Mr. Richard in any manner other than as allowed 

by 40 CF.R., Stibtitle A, Part 9. 

Page 1 of3 
08/17/2011 10.04 FAX 2024935142 FAA - DMS 1^003/023 

AUG. 16. 201 ! 5:09P M REGULATORY AFFAIK S UO. 2=;O P. 3/2 3 

3. FedEx and Corporate Air respectfully disa^^ee with the interpretation of the 

F A A in citing the Memorandum attached as an exhibit to its Motion, While 

the Memorandum, notably an interpretation of the rules by a DOT auomey, 

clearly addresses that a former employee is not prohibited from testifying 

about matters that he did not participate in or wi^rk on w-hile a DOT 

employee, the Memorandum does not imply by omission that all testimony 

about matters a former employee did participate in or work on is, 

conversely, prohibited. In fact, such testimony is expressly allowed, as 

shown in the letter to Mr. Richard from the Deputy Chief Counsel for 

PHMSA , Sherri Pappas, which the FA A included in its Supplement to 

Motion in Limine and Reque.'n for Expedited Hearing filed August 11, 201L 

4. Mr. Richard received permission to testify via email on August 15, 2011, 

from Deputy Chief Counsel Pappas, as required under 49 GF.R. 9.7(b), per 

the attached document. 

5. Furthermore, FedEx and Corporate Air have cooperated with the Agency 

(PHMSA) by providing a list of anticipated questions to ensure that the 

subject matter and information solicited does not in any way expose Mr. 

Richard to scrutiny under his post-employment dtides, cither under contract 

or by regulation. 

WHEREFORE, PREMISES CONSIDERED, FedEx and Corporate Air 

respectfully submit that the FAA's Motion in Limine should be denied, as the Agency 

Attorney has provided approval as required under the regulations, and as a former 

Page 2 of 3 
08/17/201 1 100 4 FAX 2024935142 FAA ^ DMS g]004/02 3 

All!:, 16- 2011 5:[i9PM REGULATOR?? AFFAlJlS fJO. 240 P. 4/23 

employee is not forbidden from testifying to matters on which he worked, as argued by 

the FAA. 

Respectfully submitted this 16^ day of August, 2011. 

CyntEiTChandJer-Snel], Senior Coainsel 

Federal Express Corporation 

Corporate Air 

3620 Hacks Cross Road 

Building B, 3"* Floor 

Memphis, TN 38125 

901-434-8361 

901-434-8283 fax 

f^yrrthiaciVa^filcr-5neIi(Q)fedex.com 

CERTIFCATE OF SERVICE 

I hereby certify that the foregoing has been served via FedEx Priority Overnight 

on this 16°* day of Atigust, 2011, to the following: 

The Honorable Richard C. Goodwin 

Office of Hearings, M-20 

1200 New Jersey Avenue, SE 

East Building Ground Floor, Rm E12-320 

Washington, DC 20590 

202-366-2139 

202-366-7536 fax 

Federal Aviation Admirustration 

800 Independence Avenue SW 

Washington, DC 20591 

Atin. Hearing Docket Clerk AGC-43 0 

Wilbur Wright Building. Suite 2W1000 

202-493-5142 fax 

Kyle Lomazow, FAA Attorney 

FAA Office of Regional Counsel 

1601 Lind Ave. SW 

Renton, W A 98057 

425-227-1847 

425-227-1007 fax 

-Snell 

Page 3 of 3 
08/17/201 1 10:04 FAX 2024935142 FAA - OMS (2|005/023 

AUG. IS. 2011 5:09PM ^hGULATORY AFFAIRS NO. 2^18 PiP. 5/233 

Cynthia Chandler-Snell 

From: sherri .pappas@dot.gov 

Sent: Monday. August 15, 2011 1:02 PM 

To; Cynthia Chandler-Snell 

Subject: RE: Revised proposed questions for Bob Richard 

Cynthia, 

As you are aware Bob may testify under oath under penalty of perjury if the testimony is within the confines of 

49 CFR Part 9 and IS USC 207 and 5 CFR Part 2641. To recapIn any legal proceeding in which the United States {including any federal agency or officer of the United States) 

is a party: 

An employee tinduding a former employee) may not testify as an expert or opinion v^^itness, with regard to any 

matter arising out of the employee's official duties or the functions of the Department, for any party other than 

the United States in any legal proceeding in which the United States Is a parry. An employee who receives a 

demand to testify on behalf of a party other than the United States may testify as to facts within the employee's 

personal knowledge, provided that the testimony be subject to the prior approval of agency counsel and to the" 

Federal Rules of Civil Procedure and any applicable claims of privilege. An employee may not purport to speak 

for DOT or disclose any confidential, sensitive information or anything about the deliberative process of DOT. 

The post employment restrictions are in 18 USC 207 and 5 CFR part 2641. The exception for testimony Is In IB 

USC 207(j){6). Under this exception an employee is not prevented from E'^ing testimony under oath or from 

making statements required to be made under penalty of perjury. However, this exception does not apply to 

the former employee serving as a expert witness with respect to a particular maner for any person (except the 

US) in that matter. 5 CFR 2641.301(f) implements this provision for giving testimony under oath as long as you 

are not serving as an expert witness. 

As applied to your proposed set of questions, it looks like the questions are intended to elicit testimony based 

on facts within Bob Richard's personal knowledge. The questions will not ask for his opinion as an expert. The 

questions will as for information that is within Bob's personal knowledge or is public information. The questions 

will not elicit testimony that will disclose any confidential information or anything about the deliberative process 

of PHMSA or DOT. I have no objections to the proposed set of questions. 

Sherri Pappas 

Deputy Chiaf Counsel 

Office of Chief Counsel 

Pipeline and Hazardous Materials Safety Administration 

U.S. Department of Transportation 

1200 New Jersey Avenue SE 

E26-334 . 

Washington. DC 20590 

202-36S-4363 

sherri. pappastajdo^, gov 

S/15/?,011 
08/17/201 1 10:04 FAX 2024935142 FAA " OMS 0006/02 3 

AU(^. 16.2011 5:D9P(v] SEGULATOIiY AFF.MiiS l\!0. 243 ?. 6/2 : 

UNITED STATES OF AMERICA 

DEPARTMENT OF TRANSFORATION 

OFFICE OF HEARINGS 

WASHINGTON, DC 

In the Matter of "EAA DOCKET NO CP 10NM0006 

FEDERAL EXPRESS CORPORATION . FAA CASE NO 2009NM700056 

In the Matter of FAA DOCKET NO CP10NM0007 

EMPIRE AIRLINES INC FAA CASE NO 2009NM700065 

FEDEX AND EMPIRE'S RESPONSE TO FAA\S MOTION IN LIMINE 

AND RBOUEST FOR EXPEDITED RULING 

THE HONORABLE RICHARD C. GOODWIN 

COME NOW the Respondents, Fe<l«raJ Express Corporation (hereinafter 

"FedEx'^ and Empire Airlines, Inc. (hereinafter "Empire"), and in response to the FAA'S 

Motion in Limine and Request for Expedited Ruling submits the following: 

1. It is admitted that FedEx, Empire, and the FAA exchanged discover>- on the 

agreed-upon date of August 8, 2011, wherein FedEx and Empire named Bob 

Richard as a potential witness. 

2. It is admitted that Mr. Richard is the former Deput>' Administrator for 

Hazardous Material Safet>^ for the Pipeline and Hazardous Materials Saiety 

Administration (PHMSA). FedEx and Empire agree that there are 

requirements governing the matters and extent to which Mr. Richard may 

testify, uiiich were addressed in the discovery response. FedEx and Empire 

did not name Mr. Richard as an expert or opinion ^^•itnes5 and have no 

intentions of using Mr. Rjchard in any manner other than as allowed by 40 

C.F.R., Subtitle A, Part 9. 

Page 1 of 3 
08/17/201 1 10:04 FAX 2024935142 FAA - DMS 2|007/02 3 

AUG. 16.2011 5:09PM fiEGULATORY AFF.MiiS NO. 245 ' P. l/l l 

3. FedEx and Empire reapectfiilly disagree with the interpretation of the F.AA 

in citing the Memorandum attached as an exhibit to its Motion. While the 

Memorandum, notably an interpretation of the rules b>' a DOT attomc>-, 

clearly addresses that a former employee is not prohibited from testif>'ing 

about matters that he did not participate in or work on while a DOT 

employee, the Memorandum does not imply by omission that all testimony 

about matters a former employee di^ participate in or work on is, 

conversely, prohibited. In fact, such testimony is expressly allowed, as 

shov-Ti in the letter to Mr. Richard from the Deputy Chief Counsc] for 

PHMSA, Sherri Pappas, which the FAA included in its Supplement to 

Motion in Limine and Request for Expedited Hearing filed August 11, 2011. 

4. Mr. Richard received pemtission to testif>' via email on August 15, 2011, 

from Deputy Chief Counsel Pappas, as required under 49 CF.R, 9.7(b), per 

the attached document. 

5. Furthermore, FedEx and Empire have cooperated v,ith the Agency 

(PHMSA) by providing a hst of anticipated questions to ensure that the 

subject matter and information solicited does not in any way expose Mr. 

Richard to scrutiny under his post-cnaploymcm duties, cither tmder contract 

or by legulation. 

WHEREFORE, PREMISES CONSIDERED, FedEx end Empire respectfully 

submit that the FAA's Motion in Limine should be denied, as the Agency Attorney has 

provided approval as required under the regulations, and as a former employee is not 

forbidden from testiiyine to matters on which he worked, as argued by the FAA. 

Page 2 of 3 
08/17/201 1 10:05 FAX 2024935142 FAA ^ DMS 121008/023 

AUG. !^. 20! l 5:09FM REGULATOf^Y AFFAi.^S NO. 246 ?. 8/23 

Respectfully submitted thi s 16* day of August, 2011. 

Cynthia Chandler-Snell 

Senior Counsel 

Federal Express Corporation 

Empire Airlines 

3620 Hacb; Cross Road 

Building B, 3"* Floor 

Memphis, TN 38125 

901-434-8361 

90M34-8253 fax 

cvnthi 3„ chandler-snellt^fedex. com 

CERTIFCATE OF SERVICE 

I hereby certify that the foregoing has been aer.'ed via FedEx Priority Overnight 

on this 16* day of August, 2011. to the following: 

The Honorable Richard C. Good\*in 

Office of Hearings, M-20 

1200 New Jersey Avenue, SE 

East Buildijig Ground Floor, Rm E12-320 

Washington, DC 20590 

202-366-2139 

202-366-7536 fax 

Federal Aviation Administration 

800 Independence Avenue SW 

Washington, DC 20591 

Attx. Hearing Docket Clerk AGC-430 

Wilbur Wright Building, Suite 2W1000 

202-493-5142 fax 

Kyle Lomazow, FA A Attorney 

F A A Office of Regional Counsel 

1601 Lind Ave. SW 

Renton, WA 98057 

425-227-1847 

425-227-11 

Pace 3 of 3 
08/17/201 1 100 5 FAX 2024935142 FAA - DMS 0009/02 3 

AUG. i6. 2011 5:09PiVl RtGULATOfiY AFFAi.^S MO. 24S Pagp. 9/23 

Cynthia Chandler-Snell 

From: 3herri-pappas@dot.gov 

Sent: Monday, August 15, 2011 1:02 PM 

To: Cynthia Chandler-Snell 

Subject: RE: Revised proposed questions for Bob Richard 

Cynthia. _^^ ..,,„,_ _ ' 

As you are aware Bob maytestify under oath under penalty ofpen'uryifthe testimony is within the confines of 

49 CFR Part 9 and 13 USC 207 and S CFR Part 2641. To recapIn any legal proceeding in which the United States (including any federal agency or officer of the United States) 

is a party: 

An employee {including a former employee) may not testify as an expert or opinion witness, with regard to any 

matter arising out of the employee's official duties or the functions of the Department, for any party other than 

the United States in any legal proceeding in which the United States is a party. An employee who receives a 

demand to testify on behalf of a party other than the United States may testify as to facts wixhin the employee's 

personal knowledge, provided that the testimony be subject to the prior approval of agency counsel and to the 

Federal Rules of Civil Procedure and any applicable claims of privilege. An employee may not purport to speak 

for DOT or disclose any confidential, sensitive information or anything about the deliberative process of DOT. 

The post employment restrictions are in IS USC 207 and 5 CFR part 2641. The exception for testimony is in 18 

USC 207(j){6). Under this exception an employee is not prevented from giving testimony under oath or from 

making statements required to be made under penalty of perjury. However, this exception does not apply to 

the former employee serving as a expert witness with respect to a particular matter for any person (except the 

US) in that matter. 5 CFR 2641.301(r') Implements this provision for giving testimony under oath as long as you 

are not serving as an expert witness. 

As applied to your proposed set of questions, it looks like the questions are intended to elicit testimony based 

on facts within Bob Richard's personal knowledge. The questions will not ask for his opinion as an expert. The 

questions will as for information that is within Bob's personal knowledge or Is public Information. The questions 

wfll not elicit testimony that will disclose any confidential information or anything about the deliberative process 

of PHMSA or DOT. I have no objections to the proposed set of questions. 

Shern Pappas 

Deputy Chief Counsel 

Office of Chief Counsel 

Pipeline and Hazardous Materials Safety Administration 

U.S. Department of Transportation 

1200 New Jersey Avenue SE 

E26'334 

Washington, DC 20590 

202-366-1363 

sherrt.pappasfa^ot.qQv 

8/15/2011 
08/17/201 1 10.05 FAX 2024935142 FAA - OMS i2]010/023 

AUU. 16.Kl] l 5:10PM i^tGUL;lTORY AFFAIRS NO. 243 P. iO/2 3 

UNITED STATBS OF .AMERICA 

DEPARTMENT OF TRANSPORATroN 

OFFICE OF HEARINGS 

WASHINGTON, DC 

In the Matter of . FAA DOCKET NO CPI ONMOO 11 

FEDERAL EXPRESS CORPORATION FAA CASE NO 200SNM700127 

In the Matter of FAA DOCKETNO CPIONMOOIO 

CORPORATE AIR FAA CASE NO 200SNM700126 

FEDEX AND CQRPORATF. AXR'R 

MOTION TO ALLOW TESTIMONY OF WITNESS DISCLOSED AFTER 

DISCOVERY DEADLINE 

THE HONORABLE RICHARD C. GOODWIN 

COME NOW the Respondents, Federal Express Corporation (hereinafter 

"FedEx") and Corporate Air, and move this Honorable Court to allow the Respondents to 

call a witness v/ho was disclosed to the FAA after the disco^'ery deadline. In support of 

this motion^ the Respondents submit that the FAA vdU not be prejudiced by this late 

disclosure, as discovery in these matters was extended by verbal agreement of the parties 

until Monday,. August 8, 2011, and this disclosure occurs only a week following that 

disclosure. 

Furthermore, the Respondents submit that the witness, Dr. Bashar DabbaS: will 

give limited testimony on the effect of any changes in transporting UN3373 shipments on 

the healthcare industry and on Ms patients. This testimony is in the public interest and 

will not in any way prejudice the FAA. In fact, the Respondents agree to provide Dr. 

Dabbas for deposition by phone if required prior to the trial of this matter, although we 

would point out that none of the parties to these matters have deposed any witaesses 

Pagel of 3 
08/17/201 1 10:05 FAX 2024935142 FAA ^W S ' @011/02 3 

Aijij. Ib.-^Ul l !);iOPVi R:G'dl.ATO^Y AhfAlRS tJO. 248 ?. ii/2 3 

listed in tlie discovery. A copy of Dr. Dabbas* Curriculum Vitae is attached and was 

provided to the FAA on the 15*day of August, 2011. 

In addition, the Respondents submit that they were not aware of the availabilit>' or 

existence of this wimess until Friday, August 12, 201L As information on the scheduled 

trial of this case spread through the companies and the transportation industr>', and as 

many sectors will be effected by the outcome of This matter other than carriers, witnesses 

have come forward requesting to appear before the court to testif>' as to the echoing 

effects of the proposed interpretation of this rule as applied to FedEx and Corporate Air. 

WHEREFORE, with good cause demonstrated, FedEx and Corporate Air 

respectfully request that the late disclosed -witness be allowed to testify at the trial of this 

matter. 

Respectfully submitted this 16* day of August, 2011. 

,ynthia Chandler-Snell 

Senior Counsel 

Federal Express Corporarion 

Corporate Air 

3620 Hacks Cross Road 

Building B, 3'^ Floor 

Memphis, TN 38125 

901-434-8361 

901-434-8283 fax 

cvnfhia.chandler-snell^.fedex.com 

Page 2 of 3 
08/17/201 1 100 5 FAX 2024935142 FAA - DMS @|0l2/02 3 

rtu^3- !ti. ZUli :: 1',1^'W KhG'JlAlOSY AfrAlRS m. 24S P. i2./23 

CERTIFCATE OF SERVICE 

I hereby certify that the foregoing has been served via FedEx Priority Overnight 

on this 16^ day of August, 2011, to the following: 

The Honorable Richard C. Goodwin 

Office of Hearings, M-20 

1200 New Jersey Avenue, SE 

East Building Ground Floor, Rm EI2-320 

Washington, DC 20590 

202-366-2139 

202-366-7536 fax 

Federal A\itition Administration 

800 Independence Avenue SW 

Washington, DC 20591 

Attn. Hearing Docket Clerk AGC-430 

Wilbur Wright Building, Suite 2W1000 

202^93-5142 fax 

JB^yle Lomazow, FAA Attorney 

FAA Office of Regional Counsel 

1601 Lind Ave. SW 

Renton, WA 98057 

425-227-1S47 

425-227-1007 fa 

Cynthia ChandlerPage 3 of 3 
09/17/2011 10:05 FAX 202493514 2 FAA 

lirivi .^cbULAlUKV ArrAi'K i 

- OMS 

m 243 

0013/02 3 

?. 13/23 

Qash^r Dabbas, MJD. Curriculum Vitae 

Professional Experience 

April 2006-Present 

Aug. 2005-Pre5eD: 

Aug. 2005'Present 

March. 2004-July 2005 

Jan. 1999-July 2005 

Jan 1998-July 2005 

Nov. 1992-July 2005 

Nov. 1992-Dec.2002 

July 1991-Nov, 1992 

July 1991-Nov, 1992 

Academic Appointment? 

Nov. 1992-Dec. 2005 

Nov. 1991-Nov. 1992 

July 19gS'June 1990 

July 1989-June 1990 

July l9S6'Jun«19a9 

Postgraduate Training 

July 199(>-Juiiel99l 

July 1989-Juiie 1990 

July lP88-Juae 1990 

Juty 1985-Juiie 1989 

July 1986-June 19S7 

Medical Education 

Sep. 1977-Aug. 1983 

Undergraduate Training 

Sep. 1982-Aus. 1983 

July 19S2-Sept. 1982 

July 1981-Oct. 19S1 

AmericaD Board Certifications 

June 1992 

Aug. 1990 

Medical and Laboratory Director, Oeaoptix Clinical Laboratory. 

Senior Htmatopathologist, Geaoptix Medical L^boratoi^'. 

President and Chief Medical 0£ficer, Cartesian Medical Group, Inc. 

President, Utah Paihology Servicfis, Inc. Salt Lake City, Utah. 

Medical Director, Electron Microscopy and IHC Laboratories, LDS Hospital. 

Designated Pathologist, Bout Mano^v Transplant Prosram, LDS HospitaJConsultant in Cardiac Pathology, University of Utah Medical Center. VA 

Medical CeLi«r, andPtimary Childien't Medical Center, Salt Lake City, Utah. 

Medical Director, Flow Cytometry Laboratory, LDS Hospital. 

Associate Pafliologist, Scott & "^/hit? Hospital &: Clinic, Temple, Texas. 

Ciiie£ Section of Inununopathobgy, Scott & White Hospital & Clinic. 

Cliaical Assistant Professor of Pathology, University of Utah. 

Assist^: Professor of Pathology, Texas A&MUnivenity Collese of Medicine. 

Associate Clinical lastructor, Wright State University. 

Guest Lecturer, Kettcriag Colleie of Medical Arts, Dayton, Ohio. 

Guest Lecturer, School of Medical Technology, Dayton, Ohio. 

Fellow in Hemftopathobgy, University of Utah Medical Center. 

Fellow in Surgical Pathology, Wright State Unjvcrsity/Kectering Medical 

Center. 

Chief Resident in Pathology, Wright State University/Ketiering Medics] Center. 

Resident in Antttomic and Clinical Pathology, Wrigfcc State Uoiversiiy. 

School of Medical Technology, Kctiering College of Medical Ans. Ohio. 

Damascus University School of MediciDC, Damascus, Syria, M.D. Degri^c. 

Rotating Interaship, Damascus University Hospitals, Damascus, Syria. 

Rotating Exismship, Departments of Internal Medicine and Surgery, University 

of Newcartle/Hartlepool General Hospital, England. 

Rotaiiog Extenwbip, Department of Internal Medicine, Wiight Slate University. 

Subspecialty Boards in Hematopaihology, 5Q92-078. 

Diplomatc. The Americaa Boards of Anatomic and Clinical Pathology, 90-126. 
08/17/201 1 10 05 

AUG, 16. 2011 

FAX 2024935142 FAA 

5;)DF.M REGULATORY AFFAiR';: 

- DMS 

NO. 24 3 

0 14/023 

Medical Licensure 

Nov. 2005-Present 

May 1990-Present 

May 1990-PTesent 

Nov. L^Pl-Prtsenr 

June 2006-Present 

Juac 1990-Prcscnt 

Honors/Awards 

June 1990 

State of California, lici!Dse#C52134 

State of Utah, licensed 90-1S2304-1205, 90-182304-9915 

State of Ohlahoma, license # 17226 

Slate of Texai. license A^JO^66 

State of Nftw York Certificate of Qualification in Cellular Immunology, 

Hematology^ General Histopafhology, and Cytopathology, # CQP31528. 

Controlled Substance License # BD24P2952 

Helen Popoway Research Award, Kettering Medical Center. 

Research Eitperieacc 

Kov.2002-.Tuly 2005 

Nov. 2001-July 2003 

July 3001-July 2005 

Nov. 2001 July 2005 

April 2001-July 2005 

April 2001-Iuly 2005 

April 2001-JuIy 2005 

March 2001-July 2005 

Jan. 2001-July 2005 

April 2001-Aug. 2001 

July 2000'JuIy 2005 

July 1989-July 1990 

April 1988 

June 1P86 

Predictive and prognostic factors for patients with multiple myeloma undergoing 

high dose chemotherapy and autologous ptem c«il rescue. 

Molecular markers and their coirelation ^vith response to theaapy and survival in 

patients with malignant gliomas. 

Anonyniiied collecDon of participant tissue and phenotj-pic data foj inclusion in 

a repository and use in genetics research studies. 

Cardiac valvulAr changes following L-VAD and R-VAD placement. 

Incidence and significance of DKA repair proteins in the tumor specimens of 

patients with malignant astrocytomas treated with irradiation and ECNU. 

PS3 MidniisinatchTepairE^eMLH-i, in Cisplatinum-reeistant human ovarian 

cancer colls. 

Mismatch repair gene MLH-1 in human ovarian cancer cells A2780. 

Ligaad expression in resting and hoimonolly induced ovarian cells. 

Identification of P53 response element in ovarian cancer cells. 

Risk factors in steroid-resistant caxdiac allograft rejection. 

N'oa-Hodgkin's Lymphoma, diagnostic difKculties, patterns of practice in the 

community, juid inter- and intra- observer diagnosis reproducibility. 

Quantitative Assessment of Non-Atypical Florid Epithelial Hypeipla^ia of the 

Breast and The Risk of Carcinoma. 

Adriamycin-induced Cardiac Toxicity and Serum Creatine Kinase Levels 

Measureinejit of Glycosylated Hemoglobins by Column Affinity and Ionic 

Exchange Chronmiography 

Publications 

False Posiuve PET Scaim Involving the Spleen in Tvo Paticnia with Aggrassive Nou-Hodsjdn Lymphoma. 

ClmNudMed. 2006;31:391-3 

Utility of Histologic Paraioefers in Screening for Antibody-mediated Rejection of the Cardiac Allograft: A 

Study of 3170 Biopsies. J Heart Lung Tiaosplant. 2005;24:2015-21. 

Histone Deacerylase Inhibitors Induce G2-checkpoinr Arrest and Apoptosis in CispUtifium-Rtsistaiit 

Ovarian Cancer Cells Associated with Overexprtssion of the BCL-2-relatcd fTotein Bad. Mol Cancer 

Ther. 2005; 4, 603-11. 
OS/17/2011 10 06 FAX 2024335142 FAA - DMS 13015/023 

huo io. /U N 5:IL)rM KMiULAlORY AFFAi.^S NO. 246 P, 15/23 

Early Failure of a Tricuspid Valve Replacement widi a MitrilVdIve Horrograft in a Heart Transplant 

Recipient J Heart Lung Transplant. 20W; 23:1460-2. 

Cell Type-Dependent Regulation of hMLHl Promoter Activity is Influenced by the Presence of Multiple 

Redundant Elements. Mol Cancer Res. 2003; 1:610-8. 

CeU Cycle Blockade and Differentiation of Ovarian Cancer C^lls by the Histone Deacetylase Inhibitor 

Trichoslatin A are Associated with Charges in p21,Rl>, and Id Proteins. Mol Cancer Thcr. 2002; lillSl90. 

EJCptession in A2780 Ovarian Cancer Cells. JBiolChem 2001; 20:276:27363-70. 

Idiopathic Hypcreosinophilic Syndrome. ASCP Check Sample. I994;H94-I. 

Chronic Myelomonocytic Leukemia. ASCP Check Sample. 1991; H9I-9-

Acute Biphemotypic LeukeiLia. ASCP Check Sample, 1991; H91-7. 

polycythemia Vera Evolving into Acme Myeloid Leukemia. ASCP Check Sample. 1991; H91-6. 

ThiomboacThrombocyiopenic Purpura. ASCP Check Path. I990;AQ5036 . 

Clinically Significant Virusea. An Update. AM T Events. I989;4.33-«9. 

The Acute Abdometi-. A Doctoral Thesis. Damascus UnivenlTy Press, 1983. 

Uiiluence of Etiology of Heart Failure on tha Prognostic Significance of HLA-Dr3 aitftr Heart 

Transplantarioa: Evidence forEohaiiced Humoral Immunity' in Idiopatiilc Dilated Cardiomyopathy. 

(Submitted for pubUcation in the American Jouma] of Tranaplantaaon). 

Ab^racts 

Cardiovascular Deaths in Heart Transplant Recipients; Doe$ the •Rejection Pattern MaUera? The 

ifltcmadonal Society of Heart and Lung Transplantation 25* Annual Meeting and Scientific Sessions. 

Philadelphia. April, 2005. 

D NA Repair Proteins as Predictive Factors for Long term Survival in Patiaits wjtb Glioblanoma 

Multiforme Receiving Post-operative Irradiation and Nitrosoureas, a Possible Role for DNA Mismatch 

Repair, P53, and ERCC!: A Radiation Therapy Oncology Group Study. ASCO Meeting, New Orleans, 

June, 2004, 

Long Term Survivors with Glioblastoma Multiforme (GBM) Treated -<viih Irradiation and 'Nitrosoureas 

Have Higher Initial Expression of Ki-67. ASCO Annual Meeting, New Orleans. June, 2004. 

Expression of DNA Repair Molecules 15 not a Significant Prognostic Puctcr for Long Term Survivori with 

Glioblastoma Multiforme (GBM) Receivmg IriBdiation and Nitrosoureas. ASCO Annual Meeting, New 

Orleans, June, 2004. 

L-ong-tem Survivor? witii Glioblastoma Multiforme Treated with Irradiation and Hitrosourea Have Higher 

Initial Expression of Ki-67. ASCO AnnusI Meeting, New Orleans, June, 200J. 

Effects of Trichostatin A on Cell Growth and the Expreasion of Cell Cycle and Apoptosis-related Factors In 

Plstinum-resistant Ovarian Carcinoma C^l! Lines. American Association of Cancer Research, Toronto, 

Canada, April, 2003. 
08/17/201 , 100 G FAX 2024935142 FAA ' DWS 30,6/02 3 

mu. lu.ZLM! ^M'JfM HtljULAIORV AFrAlRc' MO. 24o F. lb/23 

Pattial Aoric Valve Fusion Related to LVAD Support. Heart Failure and Circulatory Support Summit 

Conference, July, 2002. 

Risk Factor for Persisiem oi Recurrent Steroid-Resistant Cardiac Allograft Rejection; Is Pte-uansplanl 

Diagnosis of Idiopatfaic Dilated Cardiomyopathy a Rislc Factor Associated With Poor Outcome? American 

Hean Society Annual Meeting, May 20&1. 

?o5ter FresentatioDS 

. De.ve!orimeQE of an AssaY.fi:ir 06tecilQt!-pf.M£L^i^l5I.-aiLdK.M.uiatlQna Pains Invader PJu^^'^.^DKjfl , 

Peripheral Blood and Bone Marrow Aspirates. 

OptiniBl Preparation of He5atttoU>gic Smears. Presented at the Pan Pacific Lymphoma Conference, Maui, 

Hawaii, June 2007. 

ImmuDophenctype Associated with Down's Syndrome LeuJcemia and Transient Myeloproliferative 

Disorder. Presented st the Clinical Applications of Plow Cyiometry Aicmual Meeting, Orlando, Honda, 

Nov. 2001. 

Risk Factor for Persistent or Recorrcnt Steroid-Resistant Cardiac Allograft Rejection." Is Pre-transplap* 

Diagnosis of Idiopathic DilaTed Cardiomyopathy a Risk Factor Associatsd With Poor Outcome") Presented 

at the American Hean Association meeting in Anoheim, Ca, November, 2001 

Tha Utility of CD79a as a Marker of B-cell Lmeflge in Flow Cytometric Evaluation of Acnte Leukemifl. 

Pixsented at the CVmical Applications of Flow Cjlometry Annual Meeting, Austin, Texas^ Nov. 2000. 

Frofesslonal Society Fellowships and MerabersWps 

Interaational Academy of Patholo£y 

United Stales and Canadian Academy of Pa'^ology 

College of American Pathologists 

Aiflerican Society of H«rrratology 

American Society for Clinical Parhology 

Intfimationa] Society for Analyiical Cytology 

Clinical Cytometry Society 

Society for Hematopaihology 

hitematioTiad Society for Laboratory Hematology 

Kettering Alumni Asapciation 

Refejences 

References will be provided upon request 

3/2011 
08/17/201 1 10.06 FAX 2024935142 FAA - DMS @017/02 3 

AUG. i6. 2011 5:iO?M hEGULATORV AFFAiSS NO, 243 P. \l/2 2 

U^^ITED STATIES OF AMERICA 

DEPARTMENT OF TRANSPORATION 

OFFICE OF HEARINGS 

WASHINGTON, DC 

In the Matter of FAA DOCKLET NO CP 10NM0006 

FEDERAL EXPRESS CORPORATION FAA CASE NO 2009NM700056 

In the Matter of FAA DOCKET NO CP10NM0007 

EMPIRE AIRLINES INC FAA CASE NO 2009NM700065 

FEDEX AND EMPIRF.'S 

MOTION TO AT.LOW TESTIMONY OF WITNESS DtSCl-OSED AFTER 

DISCOVERY DEADLi;>rH 

THE HONORABLE RICHARD C GOODWIN 

COME NOW the Respondents, Federal Express Corporation (hereinafter 

"FedEx") aiid Empire AirUnes, Inc. (hereinafter "Empire")? and move this Honorable 

Court to allow the Respondents to call a witness who was disclosed to the FAA after the 

disco^very deadline. In support of this motion, the Respondents submit that the FAA will 

not be prejudiced by this late disclosure, as discovery in these matters ^vas extended by 

verbal agreement of the parties until Monday, August B, 2011, and this disclosure occurs 

only a week following that disclosure. 

Furthermore, the Respondents submit that the witness. Dr. Bashar Dabbas, will 

give limited testimony on the effect of any changes in transporting UN3373 shipments on 

the healthcare industry and on his patients. This testimony is in the public interest and 

•will not in any way prejudice the FAA. In fact the Respondents agree to provide Dr. 

Dabbas for deposition by phone if required prior to the trial of this matter, although we 

would point out that none of the parties to these matters have deposed any witnesses 

Page 1 of 3 
08/17/2011 10.06 FAX 202a935ia2 FAA - DMS 1^018/023 

.'\iJti. i6. 2011 5:riF M SEGl'LATORV AFFAU S MO. 248 ?. i3/23 

listed in the discovery. A copy of Dr. Dabbas' Curriculum Vitae is attached and was 

provided to the FAA on the IS'*' day of August, 2011. 

In addition, the Respondents submit that they were not aware of the a\'ailability or 

existence of this wimess until Friday, August 12, 2011. As information on the scheduled 

trial of this case spread through the companies and the transportation industry, and as 

many sectors will be effected by the outcome of this matter other than carriers, witnesses 

have come forward requesting to appear before the court to testify as to the echoing 

effects of the proposed interpretation of this rule as applied to FedEx and Empire. 

WHEREFORE, with good cause demonstrated, FedEx and Empire respectfijlly 

request that the late disclosed witness be allowed to testify- at the trial of this matter. 

Respectfully submitted this 16^ day of August, 2011. 

?>TitEa Chandler-Snell 

Senior Counsel 

Federal Express Corporation 

Empire Airlines 

3620 Haclcs Cross Road 

BuildmgB, 3"^Floor 

Memphis, TN 38125 

901^34-8361 

90M34-S2S3fax 

cvnthia. chandler-snellfSifedex .com 

Page 2 of 3 
08/17/201 1 10:06 FAX 2024935142 FAA - Df'^S @]018/023 

AUG. I&. 2[)i l 5:nf M iltGUlATO!<V AFFAIK S '^^•2^5 f- -'^'^23 

CFRTTFCAT E OF SERVICE 

I hereby certify that the foregoing has been served via FedEx Priority Overnight 

on this 16^ day of August, 2011, to the following: 

The Honorable Richard C. Goodwin 

Office of Hearings, M-20 

1200 New Jersey Avenue, SE 

East Building Ground Floor, Rm E12-320 

Washington, DC 20590 

202-366-2139 

202-366-7536 fax 

Federal Aviation Administration 

800 Independence Avenue SW 

Washington, DC 20591 

Attn. Hearing Docket Clerk AGC-430 

Wilbur Wright Building, Suite 2W1000 

202-493-5142 fax 

Kyle Lomazow, FAA Attorney 

FAA Office of Regional Counsel 

1601 Lind Ave SW 

Renton, WA 9S057 ' 

425-227-1847 

425-227-1007 fax 

.ynthia Chandler-Snell 

Page 3 of 3 
08/17/2011 10:06 FAX 2024935142 FAA 

AUG. 16. 2[H1 5:11PM REGULATOkV AFFAIRS 

DMS 

). 243 

121020/023 

P. 23/23 

Bushar Dabbas, M.D. Curriculum Vitae 

Professional Experience 

April 2006-Prtacni 

Aug. 2005-Presenc 

Aug. 2005-Prcsent 

March. 20fW-Ju]y 2005 

Nov. !992-Julv2005 

Jan. 1999-July2005 

Jan 1998-July 2005 

Nov. 1992-Ju]y2005 

Nov. 1992-Dtc. 2002 

Julv 1991-Nov. 1992 

July 1991-Nov. 1992 

Academic Appointments 

Nov. 1992-Dec.2005 

Nov. 1991-Nov. 1992 

July 198S-Jmi6 1990 

July 1989-JuDe 1990 

July 1986-June 1989 

Postgradaate Training 

July 1990-June 1991 

July 19B9-Junc 1990 

July 1988-Tune 1990 

July 1985-Junc 1989 

July 1986-Junc 1987 

Medical Edacition 

Sep. 1977-Aug. 1983 

Undergraduate Training 

Sep. 1982-Aug. 1983 

July 1982-Sept. 1982 

July 1981-Oci. 1981 

Americaja Board Certifications 

June 1992 

Aug. 1990 

Medical and Laboratory Dirccior, Gchopti-X Clinical Laboratoiy. 

Senior Hematopithologistj Genoptix Medical Laboratory. 

Presldool and Chief Medical Officer, Cartesian Medical Group, Inc. 

President, Utah Pathology Services, Inc. Salt Lake Cit>', Utah. 

Staff PathologiiT, LDS Hospital. 

Medical Director, Eleciron Microscopy and UiC Laboratories, LDS Hospital. 

Dtsignated Pathologist, BoQe Manow Transplanl Program, LDS Hospital. 

Consultant in Cardiac Patholosy. University of Utah Medical Center, V'A 

Medical Center, and Primary Children's Medical Center, Salt Lake City, Utah. 

Medical Director, Flow Cyromttij Laboratory, LDS Hospi^-

Associaie Fathologist, Scott i Wiilc Hospital &. Clinic, Temple, Texas. 

Chief, Section of Immunopathology. Scort & 'White Hospital & Clinic. 

Clinical Assistant Professor of Pathology, University of Utah. 

Assistant Professor of Paahology, Texas A&M Univcrsit\' College of Medicine. 

Associate Clinical Instructor, Wright State Univ-ersir>'-

Guest Lei^nu'er. Kettering College of Medical Arts, Dayton, Ohio. 

Guest Lecturer. School of Medical Technologj', Da>ton, Ohio. 

Fellow in Hematopathology, University of Utah Medical Center. 

Fellow in Suisicai Pathology, Wright State Univcnity/Kettering Medical 

Center, 

Chief Resident in Palholog>', Wright State University/Kettering Medical Center. 

Resident in Anatomic and Clinical Pathology, Wright State Un-'vcr^iy. 

School of Medical Technology, Kettering. College of Medical Arts, Ohio. 

Damascus University School of Medicine, Damascus, Syria, M.D. Dcsree. 

Rotating Internship, Damascus University Hospitals, Damascus. Syria. 

Rotating Extemship. DepartinenTS of Internal Medicine and Surgery, University 

of Newca.irle.'HartlepooI General Hospital, England. 

Rotating Extems>iip, Department of Internal Medicine, Wright Stale Universitj-. 

Subspecialty- Boards in Hematopathology, SQ92-07S. 

Diplomate. The American Boards of Anaiomic and Clinical Pathology, 90-126. 
08/17/2011 10:06 FAX 

AUG. 16. 20i i 5: 

2024935142 FAA 

1PM REGULATORY AFFAU S 

- DMS 

)J0. 248 

@]02l/023 

'•-. 21/2 : 

Medical Lic«niure 

Nov. 2005-Present 

May 1990-Presenl 

May l990-PTe5<mt 

Nov. 1991-Present 

June 2006-Present 

Jane 1990-Presfliit 

Honors/Awards 

June 1990 

State of California, license # C52134 

State ofUtah, license 1^90-182304-1205, 90-182304-9915 

Slate of Oklahoma, license U 17226 

State of Texas, license # J0466 

State of New York Certificate of Qualification in Cellular Immunology, 

Hemaiolog>', General Histcpathology, and Cytopathology, fr CQP315?.8. 

Controlled Substance Liccme i* BD2492952 

Helen Popowsy Research Award, Kettering Medical Center. 

Research Experience 

Nov. 2002-JuIy 2005 

Nov. :001-July 2005 

July 2001-July 2005 

Nov. 2001July 2005 

April 200UJuly 2005 

April 2001-Juh'2005 

April 2001-Julv 2005 

March 2001-Jub 2005 

Jan. 2001-July 2005 

April 2001-Aug, 2001 

July 2000-July 2005 

July 1989-July 1990 

.-^pril 19S5 

June 1986 

Predictive and prognostic factors for patients w*itb multiple myeloma undergoing 

high dose chemotherapy and autologous stem cell rescue. 

Molecular markers and their correlodon with response to therapy and survjva) in 

patients with malignant gliomas. 

Anonymized collection of participant tissue and phenotypit daia for inclusion in 

a repository and use.in genetics research studies. 

Cardiac \'alvular changes following L-VAD and R-VAD placement. 

Incidence and significance of DNA repair pioteini in the tumor specimens of 

patients uith malignant astrocytomas treated with irradiation and BCNU. 

P53 and mismatch repair gene MLH-1 in Cisplatinum-resistant human ovarian 

cancer cells. 

Mismatch repair gene MLH-1 in human ovarian cancer cells A2780. 

Lignnd expression jn resting and hormonaUy induced ovarian cells. 

Identification of P53 response element in ovarian cancer cells. 

Kisfc factors in steroid-resistant cardiac allograft rejection. 

Non-Hodgkin's Lymphoma, diagnostic difficulties, patterns of practice in the 

community, and intn-- and intrar obser\'cr diagnosis reproducibiJiTy. 

QuanctTative Assessment of Non-Atypical Florid Epithelial H>-perpJasia of the 

Breast and the Risk of Carcinoma. 

Adriamycin-Induced Cardiac Tcxicity and Serum Creatine Kinase Levels 

Measurement of Glycosylated Hemoglobins by Column Affinit>' and Ionic 

Exchange Chromatosraphy 

Publicarions 

False Positive PET Scans Involving the Spleen in Two Patients with Aggressive Non-Hodgkin Lymphoma. 

ClinNuclMed. 2006;31:391-3 

Utility of Histologic Parameters in Screening for Anabody-mediated Rejection of the Cardiac Allograft: A 

Study of 3170 Biopsies. J Heart Lung Transplant. 2005;24:2015-21. 

Histone Deacetylase Inhibitors Induce G2-checkpoint Arrest and Apoptosis in Cisplaiinum-Resistant 

Ovarian Cancci Cells Associated %vith Ovcrcxpiession of ihc BCL-2-relaied Protein Bad. Mol Cancer 

Ther. 2005; 4, 603-U, 
08/17/201 1 10.07 FAX 2024935142 FAA - OMS ^022/02 3 

AUG.16.2Cl i 5:]i^ M ,sEGULATOi;;y AFFAIRS HO. 248 r. 22/25 

Early Failure of a Tricuspid VaWe Replacement with a Mitral Valve Homografl in a Heart Transplant 

Recipient. J Heart Lung Transplant. 2004;23:1460-2. 

Cell Type-Dependent Regulation of hMLHl Promoter Activity is Influenced by the Presence of Multiple 

Redundant Elements. Mol Cancer Res. 2003; 1:610-8. 

Cell Cycle Blockade and Differentiation of Ovarian Cancer Cells by the Histone Deacet>iase Inhibitor 

Trichosratin A are Associated with Changes inp21, Rb, and Id Proteins. Mol Cancer Ther. 2002; 1:1151-

90. 

Identification of a p53 Response Element in the Promoter Region ofthchMSH2 Gene, Required for 

Expression in A27S0 Ovarian Cancer CelJa. JBiolChem 2001; 20;276:27363-70. 

Idiopathic Hypereosinophilic Syndrome. ASCP Check Sample. 1994;H94-1. 

Chronic Myelomonocytic Leukemia. ASCP Check Sample. 1991: H91-9. 

Acute Blphenotj-pic Leukemia. ASCP Check Sample, 1991; H91-7. 

Polycythemia Vera EvohTug into Acute Myeloid Leukemia. ASCP Check Sample. 1991; H91-6. 

Thromboiic Thrombocytopenic Purpura. ASCP Check Path. 1990;AQ5036. 

CiinicaUy Significant Vinises: An Update. AMTEvcnts, 1989;4:83-89. 

The Acute Abdomen: A Doctoral Thesis. Damascus University Press, 19S3. 

Influence of Eiiolog>' of Hean Failure on the Prognostic Significance of HLA-Dr3 after Heart 

Transplantation: Evidence for Enhanced Humoral Iminunit>- in Idiopathic Dilated Cardiomyopaihy. 

(Submitted for publication in the American Journal of Transplantation). 

Abstracts 

Cardiovascular Deaths in Heart Transplant Recipients: Does tlie Rejection Pattern Matters? The 

International Society of Heart and Lung Transplantation 25* Annual Meeting and Scientific Sessions. 

Philadelphia, ApriL 2005. 

DNA Repair Proteins as Predictive Factors for Long term Survival in Patients with Glioblastoma 

Multifoime Receiving Post-operative Inadiaiion and Nitrosoureas, a Possible Role for DNA Mismatch 

Repair, P53, and ERCC!: A Radiation Therapy Oncolog>- Group Study. ASCO Meeting, New Orleans, 

June, 2004. 

Long Term Survivors with Glioblastoma Multiforme (GBM) Treated with Irradiation and Nitrosoureas 

Have Higher Initial Expression of KJ-67. ASCO Annual Meeting, New Orleans, June, 2004. 

Expression of DNA Rjepair Molecules is not a Significant Prognostic Factor for Long Term Sur^ivora with 

Glioblastoma Multiforme (GBM) Receiving Irradiation and Nitrosoureas. ASCO Annual Meeting, New 

Orleans, June, 2004. 

Long-tem Survrvois with Glioblastoma Multifonnc Treated with Irradiation and Nitrosourea Have Higher 

Initial Expression of Ki-67. ASCO Annual Meeting, New Orleans, June, 2004. 

Effccu of Tricho5tatin A on Cell Growth and the Expression of Cell Cycle and Apopiosis-related Faaors in 

Platinum-resistant Ovarian Corcinoma Cell Lines. American Association of Cancer Research, TorontOj 

Canada, April, 2003. 
08/17/201 1 100 7 FAX 2024935142 FAA - OMS ©023/02 3 

n'ji:. 10. .'UN r:M|-T/i Kt(iULAKJf\Y AFrAl^iS NO. 34; ?. 23/23 

Panial Aortic Valve Fusion Related to LVAD Support Heart Failure and Circulatory Support Summit 

Conference. July. 2002. 

Risk Factor for Pcr^istem or Recurrent Steroid-Resistant Cardiac Allograft Rejection: Is Pre-transplant 

Diagnosis of Idiopathic Dilat^ Cardiomyopailiy a Risk Factor Associated With Poor Outcome'' American 

Heart Society Aimual Meetings May, 2001. 

Po?t*r Pr^.sentatioDS 

Development of an ,'^5say for Detectioo of MPL W515L and K Mutations Using Invader Plus Reagaits in 

Peripheral Blood and Bone Marrow Aspirates. 

Optimal Prerparation of Hematologic Smears. Presented at the Pan Pacitlc Lymphoma Conference, Maui, 

Hawau, June 2007. 

Immunophenotype Associated with Down's Syndrome Leukemia and Transient Myeloproliferative 

Disorder. Prescnrcd at the Clinical AppUcations of Flow Cvrometry Annual Meeting, Orlando, Florida, 

Nov. 2001. 

Risk Factor for Persistent orKecunmt Steroid-Resistant Cardiac Allograft Rejection: Is Pre-Lranspiant 

Diagnosis of Idiopathic Dilared Cardiom3'oparhy a Risk Faaor Associated With Poor Outcome? Presented 

at the American Heari Association meeting in Anaheim, Ca, Kovember, 2001 

The Utility of CD79a as a Marker of B-cell Lineage in Flow Cytometric Evaluation of Acute Leukemia. 

Presented at the Clinical Applications of Plow Cytometry Annual Meeting, Austin, Te.\as, Mov. 2000. 

Professional Society Fellowships and Memberships 

International Academy of ?atbolog>' 

United Slates and Canadian Academy of Pathology 

College of American Pathologists 

American Society of Hematology 

American Society for Clinical Pathology 

International Society lor Anabtical Cjlolog)' 

CiinicaJ Cytometry Society 

Societj- for Hematopaihology 

International Societ>' for Laboratory Hematology 

Kettering Alumni Association 

References 

References will be provided upon request 

3/20 U